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Introduction
Primary hypothyroidism is one of the most common 
endocrine disorders and typically requires lifelong 
treatment with thyroid hormone [1]. Levothyrox-
ine (LT4) is the mainstay of replacement therapy, 
and the World Health Organization considers LT4 
tablets as an essential medicine for basic health care 
(https://list.essentialmeds.org/). Although the manage-
ment of hypothyroidism with LT4 tablets is gener-
ally described as “simple, cheap, effective, and safe”, 
physicians may encounter several difficulties during 
treatment [2–5]. LT4 is classified as having a narrow 
therapeutic index, indicating that small differences in 
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Abstract 
Introduction: Over the past several years new evidence on the management of hypothyroidism has emerged, which has influenced 
recommendations from professional bodies. The presentation of hypothyroid patients has also changed, and new cases are increasingly 
diagnosed by indiscriminate screening, often identifying cases with minor biochemical disturbances. Little is known about the physician 
responses and attitudes to this changing landscape. THESIS (Treatment of Hypothyroidism in Europe by Specialists: an International 
Survey) is a large-scale survey of European physicians who treat patients with hypothyroidism. Here we document current practices of 
Polish physicians relating to the use of thyroid hormones in hypothyroid and euthyroid patients.  
Material and methods: Members of the Polish Society of Endocrinology were invited to participate in the web-based THESIS survey.
Results: In total 423 (54.6% of the 774 invited) physicians completed the survey. The majority of respondents (74.2%) would prescribe 
thyroid hormones for euthyroid patients for certain indications, such as female infertility with elevated thyroid antibodies (63.4%), simple 
goitre (40.9%), unexplained fatigue (12.1%), obesity (9.7%), hypercholesterolaemia (9.0%), and depression (9.2%). Nearly all physicians 
(96.0%) declared that the treatment of choice for hypothyroidism is levothyroxine (LT4). However, around one-third (30.3%) were also 
using LT4 and liothyronine (LT3) combination treatment; LT3 alone was rarely prescribed (1.7%), and none prescribed desiccated thyroid 
extract. The majority of respondents preferred LT4 tablets. Among alternative formulations, liquid LT4 was most commonly recommended 
for patients unable to take LT4 in the fasting state (26.0%) and patients with malabsorption (19.9%). Respondents considered prescribing 
dietary supplements (such as selenium and iodine) in hypothyroid patients with coexisting autoimmune thyroiditis (29.6%) or at the 
patients’ request (32.2%). LT4 + LT3 combination therapy was used by 32.2% when symptoms persisted notwithstanding normal serum 
TSH concentration. Psychosocial factors, comorbidities, and the burden of chronic disease were considered as the most likely causes of 
persistent symptoms. 
Conclusions: Apart from clinical practice recommendations, other factors influence the thyroid hormone therapy patterns. Moreover, 
certain areas of clinical practice were identified (the use of thyroid hormones in euthyroid subjects and the use of dietary supplements), 
which are not in accordance with the current evidence.  (Endokrynol Pol 2021; 72 (4): 357–365)
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health care costs and the patient experience. A recent 
survey focusing on the controversial topic of use of 
combination LT4 and LT3 treatment in hypothyroidism 
revealed that the physician’s choice of treatment was 
powerfully influenced by ongoing patient symptoms 
and characteristics independently of biochemical 
control of hypothyroidism [21]. This is a concerning 
trend given the lack of evidence for superiority of T3 
treatment and the risks of subclinical hyperthyroidism. 
LT4-only preparations have the advantage (over T3) 
of restoring physiological levels of thyroid hormones 
without the potentially hazardous fluctuations in se-
rum T3 concentration. However, physician prescribing 
choices among different thyroid hormone preparations 
has not been studied in the context of persistent patient 
symptoms. Currently, physicians’ prescribing choices 
between different thyroid hormone preparations are 
being studied in various European countries using the 
THESIS questionnaire (Treatment of Hypothyroidism in 
Europe by Specialists: an International Survey) [22–24], 
of which the present study was a part. The aim was to 
identify clinical practice attitudes of Polish physicians 
relating to treatment of hypothyroidism with a focus 
on available formulations of LT4.  
Material and methods
The online questionnaire platform Lime-Survey (https://www.
limesurvey.org/), which provides various question templates, 
was used. The THESIS questionnaire consisted of 32 questions (8 
concerning demographic data and 22 concerning thyroid hormone 
use). The English version of the questionnaire was translated into 
Polish by a bilingual clinician and checked by two bilingual senior 
physicians. Active members of the Polish Society of Endocrinology, 
whose e-mails were available on the website http://www.en.ptendo.
org.pl/, were invited to participate (n = 774), without a previous pre-
dose or blood concentrations may lead to therapeutic 
failure (under- or overtreatment) [6]. Malabsorption 
syndromes, and various drugs and foods may af-
fect T4 absorption, influencing therapy [7–9]. While 
most patients report improved well-being during LT4 
therapy, some patients remain inadequately treated 
with elevated TSH levels and/or persistent symptoms 
[10]. Moreover, online surveys of hypothyroid patients 
on LT4 tablets indicate that impaired quality of life and 
dissatisfaction with LT4 therapy is common. [11, 12]. 
Other options of thyroid hormone replacement 
therapy include the following: different LT4 formula-
tions (soft-gel capsules or liquid solution), liothyronine 
(LT3), a combination of LT4 and LT3, and desiccated 
thyroid extracts (DTE). However, the availability of 
alternative forms of thyroid hormone replacement 
therapy varies between countries [13]. Various brands 
and formulations of thyroid hormone are available to 
prescribers in Poland (Tab. 1). Only LT4 tablets pro-
duced by two different manufacturers are reimbursed 
by the National Health Fund. LT4 as a liquid solution 
has been commercially available since the last quarter 
of 2020, whereas LT4 soft-gel capsules, LT3, and DTE 
are unavailable. 
Different LT4 preparations are prescribed with 
variable frequency by endocrinologists and practi-
tioners [14]. Furthermore, national differences in the 
prescription of LT4 and a continuing upward trend 
across time, suggestive of lowering thresholds em-
ployed by physicians in initiating treatment, have been 
noted [15–17]. Switching from one LT4 preparation to 
another appears to incur a significant economic cost 
[18–20]. Understanding the prescribing preferences 
of physicians is important because it has an impact on 
Table 1. Various brands and formulations of thyroid hormones available to prescribers in Poland at the time of the survey
Thyroid hormone Pharmaceutical formulation
Name of the 
product* MAH Strength [µg] Reimbursement**
LT4 Tablet Eltroxin® Aspen Pharma Trading Ltd 50 and 100 No
LT4 Tablet Euthyrox N® Merck Sp. z o.o.
25, 50, 75, 88, 100, 
112, 125, 137, 150, 
175, and 200
Yes
LT4 Tablet Letrox® Berlin-Chemie AG 50, 75, 100, 125, and 150 Yes
LT4 Oral solution Tirosint Sol®*** IBSA Farmaceutici Italia S.r.L.
13, 25, 50, 75, 88, 
100, 112, 125, 137, 
150, 175, and 200
No
LT4 and LT3 Tablet
Novothyral®
Novothyral 75®
Merck Sp. z o.o.
100 μg LT4 + 20 μg 
LT3/tablet;  
75 μg LT4 + 15 μg 
LT3/tablet
No
Based on summary of product characteristics. LT4 — levothyroxine; LT3 — liothyronine; MAH — Marketing Authorisation Holder. *In alphabetical order. 
**Reimbursement by the National Health Fund (Narodowy Fundusz Zdrowia — NFZ). ***Tirosint Sol: date of first authorization — 21 January 2020, introduction on the 
market - the last quarter of 2020
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selection. All received an initial e-mail, including an electronic link 
to the questionnaire, followed by 4 reminders at weekly intervals 
between September 1st and 4th October 2020. Anonymized survey 
responses, accessible only via passwords, were collected and stored 
electronically by the survey service, which automatically blocked 
repeat submissions from the same IP address. 
Statistical analysis 
Questionnaires were considered valid for statistical evaluation 
only when complete demographic data were provided by re-
spondents. Descriptive statistics were prepared for responses to 
each question and presented as numbers (percentages). Pearson’s 
c2 test or Fisher’s exact test were used to compare frequencies 
(percentages) between categorical variables. Two-sided p-values 
< 0.05 were considered statistically significant. Statistical analyses 
were performed using IBM SPSS Statistics version 23 software 
(SPSS, Chicago, IL, USA). 
Results
Data about the survey respondents 
In total, 459 members of the Polish Society of Endocri-
nology (59.5% of the 774 invited) participated in the 
survey, 423 of whom (92.2%, 423 of 459) completed all 
demographic data (Tab. 2). The majority were special-
ists in endocrinology (86.8%), had more than 10 years 
of clinical practice (82.8%), and treated thyroid patients 
on a daily basis (88%). The vast majority (79%) managed 
more than 100 hypothyroid patients per year, while 
1.7% rarely treated hypothyroid patients. 
Treating patients with thyroid hormones
Around three-quarters of respondents (314 of 423, 
74.2%) would prescribe thyroid hormones for patients 
with biochemically normal thyroid function for certain 
indications (Fig. 1). The two most frequently chosen 
indications were female infertility associated with el-
evated thyroid antibodies (268 of 423, 63.4%) and simple 
goitre growing over time (173 of 423, 40.9%). Other 
rarer indications included the following unexplained 
fatigue (12.1%), obesity resistant to lifestyle interven-
tion (9.7%), severe hypercholesterolaemia (9.0%) as 
a complementary treatment, and depression resistant 
to anti-depressant medications (9.2%). 
Nearly all physicians (406 of 423, 96.0%) answered 
that the treatment of choice for hypothyroidism is 
LT4, with only one (0.2%) choosing LT3 (Tab. 3). Con-
sequently, nearly all respondents were prescribing 
LT4 in clinical practise. However, around one-third 
were also using LT4 and LT3 combination treatment 
(128 of 423, 30.3%); LT3 alone was rarely prescribed 
(1.7%), and nobody prescribed DTE. Subgroup analy-
sis revealed that physicians older than 40 years, those 
with more than 10 years medical practice, and those 
treating more than 100 hypothyroid patients per year 
more often prescribed LT4 + LT3 combination therapy 




















Internal Medicine 282 (66.7)
Paediatric Endocrinology 20 (4.7)




Polish Society of Endocrinology 406 (96)***
European Thyroid Association 45 (10.6)
American Thyroid Association 2 (0.5)
None of the above 17 (4)****
Place of employment*
University centre 194 (45.7)
Regional hospital 55 (13)
Private clinic 255 (60.1)
General practice 36 (8.5)
Basic researcher 40 (9.5)*****
Specialist practice 234 (55.3)




Treatment of patients with hypothyroidism
Rarely 7 (1.7)
10 to 50 patients/year 34 (8.0)
51 to 100 patients/year 48 (11.3)
> 100 patients/year 334 (79.0)
*the sum of percentages exceeds 100% because > 1 option may have been 
selected; **other specialties (n > 3): diabetes, surgery, paediatrics, nephrology; 
***Number of members in good standing (who paid recent fees); ****among them 
provisional and honorary members of the Polish Society of Endocrinology (who 
did not pay recent fees); *****The vast majority combined basic research with 
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(age > 40 vs. ≤ 40, 41.0% vs. 11.0%; years in practice > 10 
vs. ≤ 10, 38.1% vs. 10.5%; > 100 patients/year vs. ≤ 100 
patients/year,  37.4% vs. 11.3%; c2 test, p < 0.0001) than 
those without these characteristics.
A high proportion of responders (390 of 423, 92.2%) 
indicated that most of their patients were treated with 
the type of LT4 that they prescribed, suggesting that 
physicians in Poland are able to dictate the formulation 
of LT4 dispensed. 
Using different LT4 formulations
In all clinical situations, the majority of physicians 
preferred LT4 tablets or did not expect “major changes 
with different LT4 formulations” (Tab. 4). Among 
alternative formulations, LT4 as a liquid solution was 
preferred in some patients (110 of 423, 26.0%) who were 
unable to take LT4 in the fasting state and in patients 
with celiac disease, malabsorption, lactose intolerance, 
or intolerance to excipients (84 of 423, 19.9%). LT4 as 
soft gel capsules (which were not available in Poland 
at the time of the survey) were rarely chosen (less 
than 13% of respondents). Around a quarter of the 
respondents (109 of 423, 25.8%) chose alternative new 
formulations (liquid solution or soft-gel capsules) for 
patients on LT4 who had unexplained poor biochemical 
control of hypothyroidism, while almost half (201 of 
423, 47.5%) recommended LT4 from another manufac-
turer. Finally, 194 of 423 physicians (45.9%) expected no 
major changes in patients’ symptoms with the different 
formulations in patients treated with LT4 tablets, who, 
despite good biochemical control of hypothyroidism, 
had persistent symptoms, and 145 of 423 (34.4%) would 
prescribe LT4 tablets from another manufacturer in 
this situation.  
Monitoring of thyroid hormone treatment
After starting LT4 replacement treatment, 241 of 423 re-
spondents (57%) would recheck TSH after 8 weeks 
and 132 of 423 (31.2%) after 4–6 weeks. After switching 
from one formulation to another or from one manu-
facturer’s LT4 tablet to another, 180 of 423 physicians 
(42.6%) would recheck TSH after 4–6 weeks and 146 
of 423 (34.5%) after 8 weeks, while only few (37 of 423, 
8.7%) stated that there was no need to check thyroid 
function after changes in LT4 preparations, if the dos-
age was the same. 












First choice for the treatment of hypothyroid patients 406 (96.0) 1 (0.2) 0 0 16 (3.8%)
Thyroid hormones prescribed in clinical practice* 406 (96.0) 7 (1.7) 0 128 (30.3) 17 (4.0%)
DTE — desiccated thyroid extracts; LT4 — levothyroxine; LT3 — liothyronine; N/A (not applicable) — respondents who did not provide an answer; *The sum of 
percentages exceeds 100% because > 1 option may have been selected
Figure 1. Use of thyroid hormones in euthyroid subjects. N/A (not applicable) — respondents who did not provide an answer; 
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Dietary supplements and combination treatment 
with LT4 + LT3
The majority of respondents considered prescribing 
dietary supplements (such as selenium and iodine) in 
addition to thyroid hormone replacement in hypothy-
roid patients with coexisting autoimmune thyroiditis 
(125 of 423, 29.6%) or at the patient’s request (136 of 423, 
32.2%). On the other hand, almost one in five (77 of 423, 
18.2%) would never use dietary supplements. The use 
of supplements did not correlate with physicians’ age.
LT4 + LT3 combination therapy was considered 
by 136 of 423 respondents (32.2%) when symptoms 
persisted notwithstanding normal TSH concentration, 
although a similar percentage (120 of 423, 28.4%) stated 
that available evidence does not support combination 
treatment (Fig. 2). Physicians aged ≤ 40 years more often 
stated that combined T4 + T3 treatment should never 
be used when compared to older colleagues (44.3% 
vs. 28.2%; p = 0.003).  
Perceptions about persistence of hypothyroid 
symptoms despite normal serum TSH
Four questions in the survey referred to patients with 
LT4-treated hypothyroidism and persistent symptoms 
despite normal serum TSH. This was observed in less 
than 5% of patients by 33.1% (140 of 423) of respondents 
and in 6–10% of patients by 28.8% (122 of 423). More-
over, 36.4% (154 of 423) stated that they were seeing 
more such cases, whereas 28.1% (119 of 423) observed 
no change. The majority of physicians considered 
comorbidities (285 of 423, 67.4%), psychosocial factors 
(278 of 423, 65.7%), and the burden of chronic disease 
(264 of 423, 62.4%) as most likely causes for persistent 
symptoms (Fig. 3). Just over half of the respondents 
(223 of 423, 52.7%) disagreed with the statement that 
LT4 treatment was unable to restore normal physiology. 
Ranking of potential causes for persistent symptoms 
despite normal serum TSH is presented in Table 5. 
Subgroup analysis suggested that younger physicians 
(≤ 40 years old) considered more frequently “patient 
unrealistic expectations” (96.2% vs. 87.2%; p = 0.011) 
and “psychosocial factors” (99.0% vs. 87.9%; p = 0.001) 
as a likely cause of persistent symptoms.  Respondents 
who treated thyroid patients on a daily basis more 
often disagreed with the statement that the presence 
of underlying inflammation due to autoimmunity was 
responsible for persistent symptoms (36.7% vs. 22.5%; 
p = 0.03). Physicians who believed that persistent 
symptoms are not due to the inability of LT4 to restore 
normal physiology were less likely to prescribe combi-
nation LT4 + LT3 than physicians who believed that LT4 
does not restore normal physiology (32.7% vs. 46.4%, 
c2 test, p = 0.04).
Respondents with diagnosed hypothyroidism
Sixty-one of 423 physicians (14.6%) declared having 
a diagnosis of hypothyroidism requiring thyroid hor-
mone treatment. Among these, 26 (42.6%) experienced 








“I expect no major 





Interfering drugs may influence 
the stability of therapy. Which LT4 
preparation is, in your experience, least 
likely to be subject to variable absorption?
143 (33.8) 25 (5.9) 63 (14.9) 165 (39.0) 27 (6.4)
Choice of LT4 formulation in patient who 
self-reports intolerance to various foods, 
raising the possibility of celiac disease, 
malabsorption, lactose intolerance, or 
intolerance to common excipients
169 (40.0) 35 (8.3) 84 (19.9) 102 (24.1) 33 (7.8)
Choice of LT4 formulation for patient 
established on LT4 tablets, who has 
unexplained poor biochemical control of 
hypothyroidism
201 (47.5)* 38 (9.0) 71 (16.8) 73 (17.3) 40 (9.5)
Choice of LT4 formulation for patient with 
poor biochemical control, who is unable 
(due to busy lifestyle) to take LT4 fasted 
and separate from food/drink
110 (26.0) 52 (12.3) 110 (26.0) 106 (25.1) 45 (10.6)
Patient established on LT4, who has good 
biochemical control of hypothyroidism 
but continues to have symptoms
145 (34.3)* 17 (4.0) 20 (4.7) 194 (45.9) 47 (11.1)
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excessive tiredness/fatigue, 8 (13.1%) had tried LT4 and 
LT3 combination therapy, and 2 (3.3%) had tried DTE. 
Six physicians did not report any clinical improvement 
during LT4 + LT3 or DTE treatment, and 2 experienced 
“more energy”. Tachycardia (n = 1) and “hot flushes” 
(n = 1) were reported side effects during LT4 and LT3 
combination therapy. Only 50 of 423 physicians (11.8%) 
would consider LT4 + LT3 or DTE for themselves if they 
were to develop hypothyroidism. Nonetheless, 54 of 224 
(24.1%) physicians who would not consider T4 + T3 or 
Figure 2. Levothyroxine (LT4) and liothyronine (LT3) combination therapy in patients with hypothyroidism. N/A (not applicable) 




































Figure 3. Physician-perceived causes for persistent symptoms in patients with hypothyroidism treated with levothyroxine, despite 
normal thyroid-stimulating hormone (TSH) levels. N/A (not applicable) — respondents who did not provide an answer
70 70 70 70 70 70 70 70
223












































of having to take
medication














DTE for themselves if they became hypothyroid were 
prescribing it in their clinical practice. 
Discussion
This is the first survey documenting attitudes of Polish 
physicians related to treatment of  hypothyroidism. 
A total of 774 members of the Polish Society of Endo-
crinology were invited to participate in a web-based 
online THESIS questionnaire, of whom 423 (54.6%) 
completed the compulsory demographic data. The 
majority of respondents were specialists in endocri-
nology (367 of 423, 86.8%), treating thyroid patients 
on a daily basis. According to the Supreme Medical 
Chamber (Naczelna Izba Lekarska, https://nil.org.pl/), 
there were 1566 registered endocrinologists in Poland 
in 2020. Therefore, our survey reflected the opinion of 
23.4% (367 of 1566) of Polish endocrinologists in all age 
groups, working in the public and the private sector of 
the health care system.  
Clinical indications for treatment with thyroid 
hormones
In accordance with current guidelines, LT4 remains the 
treatment of choice for hypothyroidism in Poland. This 
was in agreement with other national THESIS investiga-
tions in Bulgaria, Denmark, and Italy [22–24]. However, 
some important deviations from evidence-based prac-
tice concerning indications for treatment with thyroid 
hormones were noted. Contrary to evidence from large 
randomized clinical trials, the majority of respondents 
(63.4%) would consider LT4 treatment in euthyroid 
females with chronic autoimmune thyroiditis and 
infertility [25, 26]. Due to frequent iodine deficiency in 
Polish pregnant females, recommendations of iodine 
intake throughout the pregnancy and LT4 treatment 
(including patients with elevated thyroid autoantibod-
ies) will be addressed in the national guidelines on the 
management of thyroid diseases in pregnancy, which 
will be updated in 2021 [27]. A significant proportion 
of physicians (40.3%) would also treat a simple goitre 
growing over time. Although treatment of benign eu-
thyroid goitre is listed as a therapeutic indication for 
LT4, the available evidence indicates that: (i) the reduc-
tion of goitre size in patients treated with TSH-lowering 
doses of LT4 is only modest and most individuals are 
ineligible for this treatment [28]; (ii) the effect of LT4 is 
transient and ceases after drug withdrawal, in contrast 
to radioiodine [29]; and (iii) exogenous subclinical hy-
perthyroidism may be associated with serious adverse 
effects (including osteoporosis [30] and cardiovascular 
adverse events [31, 32]). Finally, 1 in 10 respondents 
would inappropriately use thyroid hormones in euthy-
roid patients with unrelated illnesses (morbid obesity, 
severe depression, unexplained fatigue, and/or hyper-
cholesterolaemia) [2, 10].  
Choice of LT4 formulation
Respondents had little opportunity to use alternative 
LT4 formulations in their clinical practice, because of 
national market limitations, in opposition to Danish 
physicians, where liquid LT4 is a widely available 
treatment option [24]. An oral solution has been com-
mercially available since the last quarter of 2020, and 
it is more expensive than LT4 tablets. Therefore, in all 
suggested clinical situations, the majority of physicians 
preferred LT4 tablets in order to achieve satisfactory 
control of hypothyroidism, and they did not expect 
“major changes with different LT4 formulations”. 
Around a quarter (26.0%) of respondents would use 
liquid LT4 in patients who were unable to take LT4 in 
the fasting state, and 19.9% in patients with malabsorp-
tion, which is in accordance with a recent Polish expert 
opinion on liquid LT4 usage [33]. However, the avail-
able evidence is scarce and the precise indications and 
cost-effectiveness of alternative LT4 formulations have 
yet to be defined [7].
International guidelines indicate that a switch 
between LT4 tablets (brand name or generic) should 
be avoided, and if necessary should be followed by 
re-evaluation of serum TSH after 4 to 6 weeks. A small 
proportion of respondents (8.7%) stated that there was 
no need for biochemical assessment of thyroid status 
after such changes if the dosage remained the same. 
Taking into consideration the poor availability of liquid 
solution and soft gel capsules at the time of the study, 
physicians’ preferences should be reassessed after gain-
ing easy access to alternative LT4 formulations.
Table 5. Ranked probable causes of persistent symptoms in 
patients with hypothyroidism treated with levothyroxine, 
despite normal thyroid-stimulating hormone (TSH) levels
Ranking in order 
of importance Physician-perceived causes
1. Comorbidities
2. Psychosocial factors
3. The burden of chronic disease
4. Chronic fatigue syndrome
5. Patient’s unrealistic expectations
6. Presence of underlying inflammation due to autoimmunity
7. The burden of having to take medication
8. Inability of levothyroxine to restore normal physiology
In Table 5, the ranking of 1 is the most likely and 8 the least likely cause.  
109 of 423 (25.8%) respondents did not provide an answer. Calculated mean 
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Dietary supplements in the treatment  
of hypothyroidism
The majority of respondents considered prescribing 
dietary supplements in addition to thyroid hormone re-
placement in patients with coexisting autoimmune thy-
roiditis (29.6%), subclinical hypothyroidism (7.3%), or 
at the patients’ request (32.2%). This clinical practice is 
partially in disagreement with current evidence-based 
practice guidelines, which state that the use of dietary 
supplements (including selenium and iodine) is not 
recommended in the management of hypothyroidism, 
especially in iodine-sufficient areas [2, 3]. Nevertheless, 
in clinical practice the trend to prescribe selenium in 
autoimmune thyroiditis is noticeable among physi-
cians in Europe [34]. Although mandatory iodization 
of household salt in Poland has led to a sustainable 
optimization of iodine status in the general population, 
iodine supplementation is still necessary in pregnant 
women [35]. Poland is considered as a selenium defi-
cient country, and this may partially explain the use of 
dietary supplements in clinical practice [36]. However, 
studies using selenium supplementation in chronic au-
toimmune thyroiditis, even though significantly reduc-
ing thyroid autoantibodies [37], did not show apparent 
improvement in the clinical course of the disease [38]. 
Use of combined replacement therapy
The use of combination therapy with LT4 + LT3 re-
mains highly controversial, with conflicting results from 
published clinical trials. The available tablets in Poland 
containing LT4 + LT3 have an “unphysiological” 
high ratio of T4 to T3 (5:1), whereas it is assumed that 
thyroid hormone replacement should be provided as 
a 14:1 ratio of T4 to T3 [5,39]. LT3 preparations and DTE 
are not available in Poland; these medications may be 
accessible by ordering from other EU countries with 
a “cross-border prescription”. Nevertheless, approxi-
mately 1 out of 3 respondents would use LT4 + LT3 
combination therapy. Physicians older than 40 years, 
treating more than 100 hypothyroid patients per year, 
prescribed LT4 + LT3 more often compared to younger 
colleagues. This could imply that younger endocrinolo-
gists follow guidelines more rigorously; alternatively, 
older colleagues may be more willing to comply with 
patient requests for T3. The main indication for com-
bination therapy was the persistence of symptoms 
suggesting hypothyroidism notwithstanding TSH 
within the normal range (32.2%). The same approach 
was shared by 43.2% of Italian and 24.2% of Bulgarian 
physicians [22, 23]. This is in keeping with international 
guidelines, provided other autoimmune diseases and 
comorbidities have been ruled out [2–4]. On the other 
hand, almost the same percentage (28.4%) would not 
expect any improvement from this therapy. Further 
well-designed randomized clinical trials in selected 
patients with persistent symptoms are called for [39, 40].
An important part of the survey concerned the 
behaviour of physicians with hypothyroidism in rela-
tion to their own treatment. A minority of physician 
respondents with hypothyroidism (10 of 61, 16.3%) 
had tried LT4 and LT3 combination treatment or DTE, 
without any significant improvement. Also, a minor-
ity of respondents (11.8%) would consider LT4 + LT3 
combination treatment or DTE for themselves if they 
were to develop hypothyroidism.  
Perceptions about persistence of hypothyroid 
symptoms despite normal serum TSH
A subset of patients with hypothyroidism treated with 
LT4 report impaired quality of life compared to controls 
and are not satisfied with their current therapy or their 
physicians [11, 12]. Despite serum TSH levels within 
reference values, these patients complain of persistent 
symptoms, which they attribute to hypothyroidism, 
including problems with weight management, fatigue, 
memory impairment, and mood disturbances. Indeed, 
this phenomenon was observed in up to 10% of patients 
by the majority of respondents (61.9%). The majority of 
physicians attributed these symptoms to comorbidities 
(67.4%), psychosocial factors (65.7%), and/or the burden 
of chronic disease (62.4%). On the other hand, “inability 
of LT4 to restore normal physiology” was the least likely 
explanation for persistent symptoms, despite evidence 
indicating that T4 monotherapy may be associated 
with low serum T3 levels. A similar view is shared by 
Bulgarian physicians, except placing the burden of 
chronic diseases above the psychosocial factors [22]. 
The current knowledge on this subject is still limited 
and further studies are awaited. 
Concluding remarks
Apart from clinical practice recommendations, coun-
try-specific factors (including the availability and costs 
of various preparations) influence the thyroid hormone 
therapy patterns. Moreover, certain areas of clinical 
practice were identified (the use of thyroid hormones in 
euthyroid subjects and the use of dietary supplements), 
which are not in accordance with current evidence or 
guidelines [22, 23, 13–15].
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